ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

I-ELCAP Results Internally Inconsistent, Peter Bach Writes

June 24, 2011

Also FDA clarifies data requirements for phase I IND applications.

April 29, 2005

December Business & Regulatory Report included in this issue.

December 12, 2003

NCI Contract Awards

November 1, 1996

Amazon Links To NCI Materials, A First For NIH Health Content.

July 14, 2000

FDA Ponders Standards For “Retrospective Prospective” Studies

January 30, 2009